Immunization with Live and Dead *Chlamydia muridarum* Induces Different Levels of Protective Immunity in a Murine Genital Tract Model: Correlation with MHC Class II Peptide Presentation and Multifunctional Th1 Cells

Hong Yu, Karuna P. Karunakaran, Isabelle Kelly, Caixia Shen, Xiaozhou Jiang, Leonard J. Foster and Robert C. Brunham

*J Immunol* 2011; 186:3615-3621; Prepublished online 4 February 2011; doi: 10.4049/jimmunol.1002952

http://www.jimmunol.org/content/186/6/3615
Immunization with Live and Dead *Chlamydia muridarum* Induces Different Levels of Protective Immunity in a Murine Genital Tract Model: Correlation with MHC Class II Peptide Presentation and Multifunctional Th1 Cells

Hong Yu,* Karuna P. Karunakaran,* Isabelle Kelly,† Caixia Shen,* Xiaozhou Jiang,* Leonard J. Foster,† and Robert C. Brunham*

Mice that were intranasally vaccinated with live or dead *Chlamydia muridarum* with or without CpG-containing oligodeoxynucleotide 1862 elicited widely disparate levels of protective immunity to genital tract challenge. We found that the frequency of multifunctional T cells coexpressing IFN-γ and TNF-α with or without IL-2 induced by live *C. muridarum* most accurately correlated with the pattern of protection against *C. muridarum* genital tract infection, suggesting that IFN-γ–producing CD4+ T cells that highly coexpress TNF-α may be the optimal effector cells for protective immunity. We also used an immunoproteomic approach to analyze MHC class II-bound peptides eluted from dendritic cells (DCs) that were pulsed with live or dead *C. muridarum* elementary bodies (EBs). We found that DCs pulsed with live EBs presented 45 MHC class II *C. muridarum* peptides mapping to 13 proteins. In contrast, DCs pulsed with dead EBs presented only six MHC class II *C. muridarum* peptides mapping to three proteins. Only two epitopes were shared in common between the live and dead EB-pulsed groups. This study provides insights into the role of Ag presentation and cytokine secretion patterns of CD4+ T effector cells that correlate with protective immunity elicited by live and dead *C. muridarum*. These insights should prove useful for improving vaccine design for *Chlamydia trachomatis*.

*Chlamydia trachomatis* is an intracellular pathogen responsible for >92 million sexually transmitted infections and 85 million ocular infections per year worldwide (1). Sexually transmitted *C. trachomatis* is a major cause of long-term disease sequelae in women such as infertility and ectopic pregnancy (2, 3). The “seek and treat” programs to prevent and control *C. trachomatis* in comparison with dead organisms and previously demonstrated that dendritic cells (DCs) exposed to live or dead *C. muridarum* develop into distinct phenotypes. In particular, DCs exposed to live *C. muridarum* became mature and stimulated Ag-specific CD4 T cells, whereas DCs exposed to dead *C. muridarum* were inhibited in acquiring a mature phenotype. Costimulation of DCs with dead EB and CpG-containing oligodeoxynucleotide (CpG-ODN) partially overcame dead EB inhibition of DC maturation (11). Our laboratory has also investigated the transcriptional responses of bone marrow-derived DCs following exposure to live and dead *C. muridarum* using GeneChip microarrays. The study revealed marked differences in CXC chemokine profiles in DCs exposed to live or dead organism (12). In aggregate, the data demonstrate that DCs exposed to live EBs are phenotypically and functionally distinct from DCs generated by exposure to dead EBs. We therefore hypothesized that differences in DC maturation phenotype may contribute to differences between immunogenicity of live versus dead EBs.

Immunity to *C. muridarum* infection is known to be largely cell-mediated and is therefore dependent on *Chlamydia*-derived peptides presented to CD4 T cells via MHC molecules on APCs (13, 14). Recently our laboratory used an immunoproteomic approach (15–17) to identify *C. muridarum* T cell Ags, which was based on isolating and sequencing of pathogen-derived peptides binding to MHC class II molecules presented on the surface of DCs after they were pulsed with live EBs. We identified 13 *C. muridarum* peptides derived from eight novel epitopes (18). These peptides were recognized by Ag-specific CD4 T cells in vitro and recombinant proteins containing the MHC binding peptides were able to induce partial protection via immunization against *C. muridarum* infection in vivo (19). To investigate additional mechanisms behind differences in protection between dead and live EBs at the level of Ag presentation, we hypothesized that the type of pathogen...
peptides presented by MHC molecules may differ when DCs are pulsed with dead and live EBs.

The immune correlates for protection against *C. trachomatis* infection are known to be IFN-γ-mediated Th1 immune responses (20–22). However, other infection model systems have shown that using IFN-γ as a single immune correlate may not be sufficient to screen for protective immunity. Interestingly, this has been also observed for *C. muridarum* following adoptive transfer of CD4+ T cell clones (23). Flow cytometry allows assessment of individual cytokines simultaneously on a single-cell basis. Recent reports describing various disease targets in different animal models have demonstrated a correlation between protection and high-quality T cells that coexpress multiple cytokines (24–26). One of the effector cytokines shown in these studies mediating control of intracellular infection is TNF-α. TNF-α in combination with IFN-γ can synergize to mediate killing of pathogens (27). IL-2 has no direct effector function but strongly enhances the expansion of effector T cells. Therefore, it is of interest to use a cytokine set of no direct effector function but strongly enhances the expansion of dead EBs.

**Materials and Methods**

**Chlamydia**

*C. muridarum* mouse pneumonitis strain Nigg was grown in HeLa 229 cells in Eagle’s MEM (Invitrogen) supplemented with 10% FCS. Elementary bodies were purified by discontinuous density gradient centrifugation as previously described (28). Purified EBs were aliquoted and stored at −80°C in sucrose-phosphate-glutamic acid buffer and thawed immediately before use. The infectivity and the number of inclusion-forming units (IFU) of purified EBs were determined by immunostaining using anti-EB mouse polyclonal Ab followed by biotinylated anti-mouse IgG (Jackson ImmunoResearch Laboratories) and a diaminobenzidine substrate (Vector Laboratories) (29). Dead EBs were prepared either by heating to 56°C for 30 min or by exposure to ultraviolet light from a G15T8 ultraviolet lamp (D. William Fuller, Chicago, IL) at a distance of 5 cm for 45 min at room temperature as previously described (8). Viability was tested on HeLa 229 cells to ensure complete inactivation of the heat- or ultraviolet-treated EBs. The IFU for both live and dead EBs were calculated from the titers determined on original *C. muridarum* EB-purified stocks as described above.

**Mice**

Female C57BL/6 mice (5 to 6 wk old) were purchased from Charles River Canada and housed under pathogen-free conditions at the Animal Facility of the Jack Bell Research Center. All experiments were performed in strict accordance with University of British Columbia guidelines for animal care and use.

**Immunization**

Three groups of mice were immunized with 1) 1500 IFU live EBs intranasally once, 2) 5 × 10⁸ IFU dead EBs plus 20 μg CpG-ODN 1826 (5′-TCCATGACGTTCCGACTGTT-3′, phosphorothioate modified; Integrated DNA Technologies) intranasally three times at 2-wk intervals, and 3) 5 × 10⁸ IFU dead EBs intranasally three times at 2-wk intervals. A nonvaccinated group was included as a naive control.

**Genital tract infection challenge and *C. muridarum* quantification**

Five weeks after the live EB immunization and 1 wk after the last dead EB immunization, mice were injected s.c. with 2.5 mg medroxyprogesterone acetate (Depo-Provera; Pharmacia and Upjohn). One week after medroxyprogesterone acetate treatment, mice were challenged intravaginally with 1500 IFU *C. muridarum*. Cervicovaginal washes were taken at day 6 postinfection and were stored at −80°C for *Chlamydia* titration on HeLa cells as described previously (29).

**Multiparameter flow cytometry**

Six weeks after the live EB immunization and 2 wk after the last dead EB immunization or 1 wk after live EB challenge, mice from specified groups were sacrificed and cells harvested from spleen were stimulated with killed EBs (5 × 10⁵ IFU/ml) in complete RPMI 1640 for 4 h at 37°C. Brefeldin A was added at a final concentration of 1 μg/ml, and cells were incubated for an additional 12 h before intracellular cytokine staining. Cells were surface stained for CD3, CD4, and CD8 as well as with the viability dye, red fluorescent reactive dye (L23102; Molecular Probes), followed by staining for IFN-γ, TNF-α, and IL-2 by using a BD CytoPerm Plus Fixation/Permeabilization (BD Pharmingen) kit. Finally, the cells were resuspended in a 4% formaldehyde solution. All Abs and all reagents for intracellular cytokine staining were purchased from BD Pharmingen except where noted. We collected 200,000 live splenocytes per sample by using a FACSAria flow cytometer (BD Biosciences) and analyzed the data by using FlowJo software (Tree Star).

**DC pulsing with live or dead EBs**

DCs were generated as previously described (30). Briefly, bone marrow cells were isolated from the femurs of C57BL/6 mice and cultured in Falcon petri dishes at 4 × 10⁵ cells in 50 ml DC medium. DC medium was IMDM supplemented with 10% FCS, 0.5 mM 2-ME, 4 mM l-glutamine, 50 μg/ml gentamicin, and 5% of culture supernatant of murine GM-CSF–transfected plasmacytoma X63-Ag8 and 5% of culture supernatant of murine IL-4–transfected plasmacytoma X63-Ag8, which contained 10 ng/ml GM-CSF and 10 ng/ml IL-4, respectively. The two above cell lines were kindly provided by Dr. F. Melchers (Basilia Institute, Switzerland). At day 3, half of culture supernatants were removed and fresh DC medium was added. At day 5, nonadherent cells (purity of >50% CD11c⁺) were transferred to new dishes and cultured at 25 × 10⁵ cells in 50 ml DC medium containing 25 × 10⁵ IFU live EBs or dead EBs, respectively, at 37°C in 5% CO₂ for 12 h. The cells pulsed with live EBs or dead EBs were then harvested and stored in −80°C.

**Identification of MHC class II-bound peptides**

We acquired 6 × 10⁶ DCs pulsed with live EBs or dead EBs. The immunoproteomic approach to identify MHC class II-bound peptides from pulsed DCs involved multiple steps as previously described (18). Briefly, the pulsed DCs were lysed and MHC class II (I-Ab) molecules were purified using allele-specific anti-MHC mAb affinity columns. MHC class II molecules bound to the affinity column were then eluted and the MHC-bound peptides were separated from MHC molecules by acetic acid treatment and ultrafiltration through a 5-kDa cutoff membrane to remove high molecular mass material. The purified MHC-bound peptides were analyzed qualitatively using an LTQ Orbitrap XL (Thermo Scientific) online coupled to a nanoflow HPLC using a nanospray ionization source. The mass spectrometer was set to fragment the five most intense multiply charged ions per cycle. Fragment spectra were extracted using DTASuperCharge (http://msquant.sourceforge.net) and searched using the Mascot algorithm against a database comprised of the protein sequences from *C. muridarum*.

**Statistical analysis**

Data were analyzed with the aid of the GraphPad Prism software program. The Kruskal–Wallis test was performed to analyze data for *C. muridarum* shedding from multiple groups, and the Mann–Whitney U test was used to compare medians between pairs. Comparison of cytokine productions and mean fluorescence intensity (MFI) as determined by multiparameter flow cytometry between two groups were analyzed using two-tailed t test. A p value <0.05 was considered significant. Data are presented as means ± SEM.

**Results**

**Live and dead *C. muridarum* induce different levels of protection against *C. muridarum* genital tract infection**

We compared live to dead EBs with or without CpG-ODN 1862 using intranasal routes of vaccination. Six weeks after live EB or 2 wk after final dead EB immunization, we compared *Chlamydia* inclusion titers in cervicovaginal washes at day 6 following genital tract challenge with live EBs to measure protection. As shown in Fig. 1, excellent protection was observed in mice given live EBs intranasally. Compared to the nonvaccinated group, mice intranasally vaccinated with dead EBs formulated with CpG exhibited a partial reduction in *C. muridarum* titers in the vaginal wash (p < 0.01). Vaccination with dead EBs alone did not reduce
Collectively, the data show that the total number of IFN-γ-producing CD4+ T cells encompassed 77, 46, 6, and 0% of the total IFN-γ-producing cells in live EBs, dead EBs plus CpG, dead EBs alone, and naive groups, respectively (Fig. 4A). The MFI for IFN-γ, TNF-α, and IL-2 is an additional measure of cytokine production on a single cell basis (Fig. 4B, 4D, 4F). The MFI for IFN-γ of IFN-γ-TNF-α-IL-2 triple- and IFN-γ-TNF-α double-positive CD4+ T cells from the live EB vaccine group was significantly higher than that from other vaccine groups (Fig. 4B). Analysis of TNF-α-producing CD4+ cells also showed a correlation between the number of multifunctional Th1 cells simultaneously secreting IFN-γ, as well as TNF-α and the degree of protection among the vaccine groups (Fig. 4C). Even more impressively, the MFI for TNF-α of IFN-γ-TNF-α double-positive CD4+ T cells from the live EB vaccine groups is ~5-fold higher as compared with dead EB alone group (Fig. 4D). For IL-2–producing CD4+ cells, the fraction of IFN-γ-TNF-α-IL-2 triple-positive CD4+ T cells was associated with protection (Fig. 4E). There was no difference in the correlation of MFI for IL-2 with protection (Fig. 4F).

Cervicovaginal shedding, demonstrating that vaccination with dead EBs alone failed to induce any measurable protective immunity against C. muridarum infection.

Functional characteristics of distinct populations of Th1 responses after live or dead EB immunization

To define a correlation between characteristics of Th1 responses and protection, we used multiparameter flow cytometry and assessed Ag-specific IFN-γ, TNF-α, and IL-2–producing CD4+ T cells in mice following immunization before and after C. muridarum challenge. As shown in Fig. 2, among mice intranasally immunized with live EBs, a seven-color flow cytometry panel was used to simultaneously analyze multiple cytokines at a single cell level. A typical gating tree hierarchically identifies functional populations of CD4+ T cells based on the fluorescence staining of live cells, CD3+ cells, and IFN-γ–, TNF-α–, and IL-2–producing CD4+ T cells (Fig. 2A). CD4+ cells that express each cytokine (IFN-γ, TNF-α, and IL-2) are entered into a Boolean gating analysis that separately identifies the seven populations that express each possible combination (Fig. 2B).

To assess the characteristics of the Th1 responses in vaccinated mice, the total Ag-specific CD4+ T cell cytokine responses comprising IFN-γ, TNF-α, or IL-2 from splenocytes were measured in each of the vaccine groups, 6 wk after live EB or 2 wk after final dead EB immunization. Overall live EB intranasal immunization showed the highest number of IFN-γ–, TNF-α–, and IL-2–secreting cells per 10^6 splenocytes (Fig. 3A). The number per 10^6 splenocytes of IFN-γ, TNF-α double-positive CD4+ T cells was strikingly elevated in the live EB intranasally immunized group (Fig. 3B). The group immunized with dead EBs predominantly produced single-positive IFN-γ–producing CD4+ T cells (Fig. 3B). The nonvaccinated group (naive mice) showed very low background cytokine levels, indicating that cytokine-producing cells detected in the experimental system are C. muridarum–specific. Collectively, the data show that the total number of IFN-γ–producing CD4+ T cells is not strictly predictive of vaccine-elicted protection. Rather, protective efficiency is better correlated with cytokine coexpression profile of the CD4+ T cells.

Each cytokine-producing cells in this analysis encompasses four distinct populations. For IFN-γ, it includes IFN-γ single-positive, IFN-γ-TNF-α double-positive, IFN-γ-IL-2 double-positive, and IFN-γ-TNF-α IL-2 triple-positive CD4+ T cells. The relative percentage of the four distinct populations can help define the quality of the Th1 responses. Differences in the quality of IFN-γ, TNF-α, and IL-2 responses between vaccine groups is represented pictorially by pie charts (Fig. 4A, 4C, 4E). By quantifying the fraction of the total IFN-γ responses, we observed that the combination of IFN-γ-TNF-α IL-2 triple- and IFN-γ-TNF-α double-positive CD4+ T cells encompassed 77, 46, 6, and 0% of the total IFN-γ–producing cells in live EBs, dead EBs plus CpG, dead EBs alone, and naive groups, respectively (Fig. 4A). The MFI for IFN-γ, TNF-α, and IL-2 is an additional measure of cytokine production on a single cell basis (Fig. 4B, 4D, 4F). The MFI for IFN-γ of IFN-γ-TNF-α-IL-2 triple- and IFN-γ-TNF-α double-positive CD4+ T cells from the live EB vaccine group was significantly higher than that from other vaccine groups (Fig. 4B).

As shown in Fig. 2, among mice in

- TNF-α–, TNF-α–, and IL-2– producing CD4 T cells (Fig. 3

- TNF-α–, TNF-α–, and IL-2–se-

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p

- TNF-α–, TNF-α–, and IL-2–p
C. muridarum MHC class II-binding peptides from DCs pulsed with live EBs, but only 6 C. muridarum MHC class II-binding peptides from DCs pulsed with dead EBs (Table I). The 45 MHC class II-binding peptides identified in DCs pulsed with live EBs mapped to 13 distinct epitopes derived from 13 unique source proteins. The six MHC class II-binding peptides identified in DCs pulsed with dead EBs mapped to three distinct epitopes derived from three unique source proteins. The peptides derived from RplF and FabG were found in DCs pulsed with both live and dead EBs. There were 11 peptides, including PmpG and PmpE/F-2, found only in DCs pulsed with live EBs. Of note, our previous studies demonstrated that PmpG and PmpE/F-2 are immunodominant peptides/proteins that engender protective immunity against C. muridarum genital tract infection (19). We also compared the number of pathogen- and murine-derived MHC class II-bound peptides identified in DCs pulsed with live and dead EBs and found more peptides when the DCs were pulsed with live EBs. This was true for both C. muridarum and self-peptides and was more notable for C. muridarum-derived peptides than for self-peptides. The fold increase for pathogen-derived peptides from dead to live EB pulsing is 7.5 versus 2.2 for self-peptides (Table II). This suggests that DCs pulsed with live EBs present peptides via MHC more efficiently than do DCs pulsed with dead EBs, which in turn correlates with induction of better protective immunity by live EB immunization.

Discussion

Infection or immunization with viable intracellular pathogens typically induces immunological effects distinct from those elicited by inactivated organism (31). This also appears to be the case for Chlamydia (32, 33). For example vaccination of both humans and nonhuman primates with whole killed C. trachomatis resulted in limited protection with possible disease exacerbation upon re-infection (6, 7, 34). Strikingly, mice immunized with live C. muridarum developed complete protection (8, 35), whereas immunization with killed C. muridarum induced responses ranging from little to no protection (8), thereby providing a model system to investigate the underlying cellular and molecular basis for the failure of previous human and primate C. trachomatis vaccine trials. An understanding of differences in immune mechanisms caused by live versus dead EB immunization is important for developing safer and more effective vaccines.

FIGURE 2. Functional characterization of distinct populations of Th1 responses using multiparameter flow cytometry.

A. The staining panel and gating strategy used to identify Ag-specific IFN-γ, TNF-α, and IL-2–producing CD4+ T cells in the splenocytes from a representative mouse with intranasal live EB immunization. B. Boolean combinations of the three total cytokine gates (IFN-γ, TNF-α, and IL-2) to uniquely discriminate responding cells based on their functionality or quality with respect to cytokine production.

FIGURE 3. Ag-specific CD4+ T cell cytokine responses after EB immunization. EB-specific cytokine productions from splenocytes of vaccinated mice before challenge were analyzed by multiparameter flow cytometry. A. The total number of IFN-γ+, TNF-α+, or IL-2–producing CD4+ T cells in 10^6 splenocytes. B. The number of cells expressing each of the seven possible combinations of IFN-γ, TNF-α, and IL-2. Three or four mice were in each group. Shown are results representative of two experiments. D-EB, dead EBs; L-EB, live EBs.
elicited between live and dead organisms may serve to guide the future directions for *C. trachomatis* vaccine design.

There are two major findings reported from the present study. First, IFN-γ+–producing CD4+ T cells that highly coexpress TNF-α optimally correlated with protective immunity and were preferentially induced by live EB immunization. Second, exposure to live *C. muridarum* EBs induced DCs to present more pathogen-derived MHC class II peptides than did dead *C. muridarum* EBs.

CD4 Th1 effector cells clearly underpin *Chlamydia* immunity (13), and Igietseme et al. (23) originally demonstrated that adoptive transfer of a CD4 T cell clone specific to *C. muridarum*, which secreted both IFN-γ and TNF-α, resulted in resolution of chronic genital *C. muridarum* infection in nude mice. In contrast, a clone that produced IFN-γ alone was unable to resolve the infection in nude mice, even after 100 d, demonstrating that T cells that secrete multiple cytokines were substantially better at clearing infection than T cells with a limited cytokine profile. Building on these early promising results, we tested multiple cytokine secretion patterns at the single cell level using flow cytometry.

When using multiparameter flow cytometry in other pathogen studies, multifunctional CD4+ T cells that cosecrete IFN-γ, TNF-α, and IL-2 have been reported to better correlate with protection than IFN-γ single-positive secretion in *Leishmania major* (24) and *Mycobacterium tuberculosis* (25). Olsen et al. (36) also recently reported a high number of Ag-specific CD4+ T cells coexpressing IFN-γ and TNF-α in mice intranasally immunized with live *C. muridarum*, and in the current study, we demonstrate that IFN-γ+–producing CD4+ T cells that highly coexpress TNF-α were optimally correlated with protective immunity to *C. muridarum* genital tract challenge.

Multiple mechanisms could contribute to the enhanced protection to *Chlamydia* infection as mediated by multifunctional CD4+ T cells. First, multiple cytokines could have direct and synergistic antimicrobial action. In vitro studies have demonstrated that IFN-γ and TNF-α individually and synergistically restrict intracellular *Chlamydia* growth (37, 38). Both IFN-γ and TNF-α activate inducible NO synthase in murine cells (39), and Robinson et al. (40) demonstrated that TNF-α syn-
eragnostically enhanced IDO activity induced by IFN-γ at the level of transcription in human epithelial cells. Second, multifunctional CD4+ T cells may better correlate with protective immunity because they produce more cytokine on a per-cell basis, as recently observed higher MFI values for IFN-γ and TNF-α among triple-producers degranulating following Ag stimulation, compared with single IFN-γ producers and thus may possess better killing potential. In aggregate, the data suggest that vaccination that induces IFN-γ and TNF-α coexpressing CD4 T cells may represent the optimal correlate of protective immunity to C. trachomatis infection by one or more of these mechanisms.

Recently, we used an immunoproteomic approach to directly identify C. muridarum T cell peptides presented by APCs. Because DCs are essential to induce C. muridarum immunity via presentation of Ags to naïve T cells, we reasoned that live and dead organisms may induce presentation of different peptides. Accordingly, we compared the MHC class II-bound C. muridarum peptides identified in DCs 12 h after pulsing with live and dead organisms. We found that DCs pulsed with live EBs presented 45 MHC class II C. muridarum peptides that mapped to 13 proteins, including RplF, PmpG, and PmpE/F-2. These three C. muridarum T cell Ags have been previously identified as immunodominant. Moreover, vaccination with individual RplF, PmpG, or PmpE/F-2 recombinant proteins in mice engendered significant resistance to challenge infection in both the lung and genital tract models (19). In contrast, DCs pulsed with dead EBs led to the identification of only six MHC class II C. muridarum peptides that mapped to three proteins and included only one (RplF) of the three immunodominant C. muridarum Ags. Among the 15 epitopes presented by DCs after 12 h pulsing with live or dead EBs, 5 (RplF, FabG, PmpG, PmpE/F-2, and TC0420) were previously identified when DCs were pulsed with live organisms for 24 h (18). Thus 10 new C. muridarum T cell epitopes (TC0518, FusA, TC0884, Tuf, TC0654, TC0190, Tsf, PmpE/F-1, Atpe) were identified in the current study.

Table I. Comparison of Chlamydia- and murine-derived MHC class II-bound peptides identified in DCs after 12 h pulsing with live and dead EBs using immunoproteomics

<table>
<thead>
<tr>
<th>Peptide Sequence</th>
<th>Source Protein</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKGNEVVFSPAHHIDRPG (13)</td>
<td>Ribosomal protein L6</td>
<td>RplF</td>
</tr>
<tr>
<td>SPQGNYAAAKSAGIFS (3)</td>
<td>3-Oxoacyl-(acyl carrier protein) reductase</td>
<td>FabG</td>
</tr>
<tr>
<td>NAKTVFNLNASPIYVDA (1)</td>
<td>Polymorphic membrane protein G</td>
<td>PmpG</td>
</tr>
<tr>
<td>GAFPHLAPSANVINTGS (5)</td>
<td>Polymorphic membrane protein F</td>
<td>PmpE/F-2</td>
</tr>
<tr>
<td>GRLNVTGPKQTDVDDL (7)</td>
<td>Hypothetical protein TC0420</td>
<td>TC0420</td>
</tr>
<tr>
<td>E0TKIPITGPIAVNSTEGQN (4)</td>
<td>Pyruvate dehydrogenase</td>
<td>TC0518</td>
</tr>
<tr>
<td>GNAIPVHCIGAESQ (3)</td>
<td>Elongation factor G</td>
<td>FusA</td>
</tr>
<tr>
<td>VFWLGSKINIDDPF (1)</td>
<td>Elongation factor G</td>
<td>FusA</td>
</tr>
<tr>
<td>SVFVIPVYNSONRAPV (2)</td>
<td>Thiol-disulfide interchange protein</td>
<td>TC0884</td>
</tr>
<tr>
<td>FEVQVLSHVEEGEMQ (2)</td>
<td>Elongation factor Tu</td>
<td>Tuf</td>
</tr>
<tr>
<td>YDHIVTTGANGADIL (1)</td>
<td>Oxidoreductase</td>
<td>TC0654</td>
</tr>
<tr>
<td>LPLMIVSSKASEGGA (1)</td>
<td>Metalloprotease</td>
<td>TC0190</td>
</tr>
<tr>
<td>ISRALTPVNSNSVG (1)</td>
<td>Elongation factor Ts</td>
<td>Tsf</td>
</tr>
<tr>
<td>SRLAYQPMALASEA (1)</td>
<td>Polymorphic membrane protein E</td>
<td>PmpE/F-1</td>
</tr>
</tbody>
</table>

aNumbers in parentheses denote total number of peptides of varying length but consisting of the same core residues.

<table>
<thead>
<tr>
<th>Peptide Sequence</th>
<th>Source Protein</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Live EBs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VKGNEVVFSPAHHIDRPG (13)</td>
<td>Ribosomal protein L6</td>
<td>RplF</td>
</tr>
<tr>
<td>SPQGNYAAAKSAGIFS (3)</td>
<td>3-Oxoacyl-(acyl carrier protein) reductase</td>
<td>FabG</td>
</tr>
<tr>
<td>NAKTVFNLNASPIYVDA (1)</td>
<td>Polymorphic membrane protein G</td>
<td>PmpG</td>
</tr>
<tr>
<td>GAFPHLAPSANVINTGS (5)</td>
<td>Polymorphic membrane protein F</td>
<td>PmpE/F-2</td>
</tr>
<tr>
<td>GRLNVTGPKQTDVDDL (7)</td>
<td>Hypothetical protein TC0420</td>
<td>TC0420</td>
</tr>
<tr>
<td>E0TKIPITGPIAVNSTEGQN (4)</td>
<td>Pyruvate dehydrogenase</td>
<td>TC0518</td>
</tr>
<tr>
<td>GNAIPVHCIGAESQ (3)</td>
<td>Elongation factor G</td>
<td>FusA</td>
</tr>
<tr>
<td>VFWLGSKINIDDPF (1)</td>
<td>Elongation factor G</td>
<td>FusA</td>
</tr>
<tr>
<td>SVFVIPVYNSONRAPV (2)</td>
<td>Thiol-disulfide interchange protein</td>
<td>TC0884</td>
</tr>
<tr>
<td>FEVQVLSHVEEGEMQ (2)</td>
<td>Elongation factor Tu</td>
<td>Tuf</td>
</tr>
<tr>
<td>YDHIVTTGANGADIL (1)</td>
<td>Oxidoreductase</td>
<td>TC0654</td>
</tr>
<tr>
<td>LPLMIVSSKASEGGA (1)</td>
<td>Metalloprotease</td>
<td>TC0190</td>
</tr>
<tr>
<td>ISRALTPVNSNSVG (1)</td>
<td>Elongation factor Ts</td>
<td>Tsf</td>
</tr>
<tr>
<td>SRLAYQPMALASEA (1)</td>
<td>Polymorphic membrane protein E</td>
<td>PmpE/F-1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Peptide Sequence</th>
<th>Source Protein</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dead EBs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VKGNEVVFSPAHHIDRPG (4)</td>
<td>Ribosomal protein L6</td>
<td>RplF</td>
</tr>
<tr>
<td>SPQGNYAAAKSAGIFS (1)</td>
<td>3-Oxoacyl-(acyl carrier protein) reductase</td>
<td>FabG</td>
</tr>
<tr>
<td>KPAEEAGSIVINRVAQ (1)</td>
<td>ATP synthase subunit E</td>
<td>Atpe</td>
</tr>
</tbody>
</table>

Table II. Comparison of Chlamydia- and murine-derived MHC class II-bound peptides identified in DCs after 12 h pulsing with live and dead EBs

<table>
<thead>
<tr>
<th>Peptide Sequence</th>
<th>Source Protein</th>
<th>Abbreviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dead EBs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Murine (self) peptides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Live EBs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlamydia peptides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fold Increase</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3620 DISTINCT IMMUNE RESPONSES TO LIVE AND DEAD C. MURIDARUM
In conclusion, this study demonstrates that the cytokine secretion pattern and frequency of multifunctional T cells coexpressing IFN-γ, TNF-α, and/or IL-2 induced by live or dead Chlamydia muridarum vaccines correlates with the degree of protection against genital tract infection. Furthermore, DCs pulsed with live EBs presented more C. muridarum MHC class II peptides compared with dead EB-pulsed DCs. These findings provide mechanisms to explain the disparate protective immunity responses elicited by live and dead C. muridarum and should help guide future vaccine development for C. trachomatis.

Acknowledgments
We thank David Ko, Lindsey Laycock, and Gayle Thornbury in the Terry Fox Laboratory at the British Columbia Cancer Research Centre for providing flow cytometry services and technical assistance.

Disclosures
The authors have no financial conflicts of interest.

References